Journal of Endocrinological Investigation

, Volume 36, Issue 11, pp 1105–1111 | Cite as

Industrial endocrine disruptors and polycystic ovary syndrome

Review Article Short Review


Polycystic ovary syndrome (PCOS) is a complex and enigmatic syndrome of unknown origin and etiology enclosing a broad spectrum of phenotypic manifestations. PCOS pathophysiology combines reproductive and metabolic abnormalities into a heterogeneous disorder that has pervasive and devastating health consequences. Inquiring the generative roots of the syndrome, it has become increasingly apparent the role of the environment as a determinant factor. Experimental exposure to industrial endocrine disruptors has been related with the impairment of normal reproductive function and metabolic regulation possibly favoring the development of or aggravating PCOS-resembling clinical disorders. Industrial chemicals may reflect the contributing role of an unfavorable environment to unveil PCOS characteristics in genetically predisposed individuals or further deteriorate the hormonal and fertility imbalances of PCOS-affected females.


Endocrine disruptors PCOS 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999, 84: 4006–11.PubMedCrossRefGoogle Scholar
  2. 2.
    Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000, 85: 2434–8.PubMedGoogle Scholar
  3. 3.
    Diamanti-Kandarakis E. Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications. Expert Rev Mol Med 2008, 10: e3.PubMedCrossRefGoogle Scholar
  4. 4.
    Bates GW, Legro RS. Longterm management of Polycystic Ovarian Syndrome (PCOS). Mol Cell Endocrinol 2012, 7: e48963.Google Scholar
  5. 5.
    Diamanti-Kandarakis E, Christakou C, Marinakis E. Phenotypes and enviromental factors: their influence in PCOS. Curr Pharm Des 2012, 18: 270–82.PubMedCrossRefGoogle Scholar
  6. 6.
    Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, et al. Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocr Rev 2009, 30: 293–42.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    U.S. EPA. Special report on Environmental Endocrine Disruption: An Effects Assessment and Analysis. Office of Research and Development, 1997, EPA/630/R-96/012, Washington D.C.Google Scholar
  8. 8.
    Nelson VL, Qin KN, Rosenfield RL, et al. The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab 2001, 86: 5925–33.PubMedCrossRefGoogle Scholar
  9. 9.
    Pasquali R, Stener-Victorin E, Yildiz BO, et al. PCOS Forum: research in polycystic ovary syndrome today and tomorrow. Clin Endocrinol (Oxf) 2011, 74: 424–33.CrossRefGoogle Scholar
  10. 10.
    Uzumcu M, Zachow R. Developmental exposure to environmental endocrine disruptors: Consequences within the ovary and on female reproductive function. Reprod Toxicol 2007, 23: 337–52.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Zhou W, Liu J, Liao L, Han S, Liu J. Effect of bisphenol A on steroid hormone production in rat ovarian theca-interstitial and granulosa cells. Mol Cell Endocrinol 2008, 283: 12–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Peretz J, Gupta RK, Singh J, Hernandez-Ochoa I, Flaws JA. Bisphenol A impairs follicle growth, inhibits steroidogenesis, and down-regulates rate-limiting enzymes in the estradiol biosynthesis pathway. Toxicological Sciences 2011, 119: 209–17.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Diamanti-Kandarakis E, Piperi C. Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth. Hum Reprod Update 2005, 11: 631–43.PubMedCrossRefGoogle Scholar
  14. 14.
    Lewandowski KC, Komorowski J, O’Callaghan CJ, et al. Increased circulating levels of matrix metalloproteinase-2 and -9 in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2006, 91: 1173–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Diamanti-Kandarakis E, Livadas S, Kandarakis SA, Margeli A, Papassotiriou I. Serum concentrations of atherogenic proteins neutrophil gelatinase-associated lipocalin and its complex with matrix metalloproteinase-9 are significantly lower in women with polycystic ovary syndrome: hint of a protective mechanism? Eur J Endocrinol 2008, 158: 525–31.PubMedCrossRefGoogle Scholar
  16. 16.
    Dominguez MA, Petrea MA, Neal MS, Fostera WG. Bisphenol A concentration-dependently increases human granulosa-lutein cell matrix metalloproteinase-9 (MMP-9) enzyme output. Reprod Toxicol 2008, 25: 420–5.PubMedCrossRefGoogle Scholar
  17. 17.
    Goldman S, Shalev E. MMPS and TIMPS in ovarian physiology and pathophysiology. Front Biosci 2004, 9: 2474–83.PubMedCrossRefGoogle Scholar
  18. 18.
    Franks S, Mason H, Willis D. Follicular dynamics in the polycystic ovary syndrome. Mol Cell Endocrinol 2000, 163: 49–52.PubMedCrossRefGoogle Scholar
  19. 19.
    Franks S, Stark J, Hardy K. Follicle dynamics and anovulation in polycystic ovary syndrome. Hum Reprod Update 2008, 14: 367–78.PubMedCrossRefGoogle Scholar
  20. 20.
    Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev 2012, 33: 981–1030.PubMedCrossRefGoogle Scholar
  21. 21.
    Bates GW, Legro RS. Long term management of Polycystic Ovarian Syndrome (PCOS). Mol Cell Endocrinol 2012, 373: 91–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Baillie-Hamilton PF. Chemical toxins: a hypothesis to explain the global obesity epidemic. J Altern Complement Med 2002, 8: 185–92.PubMedCrossRefGoogle Scholar
  23. 23.
    Grün F, Blumberg B. Environmental obesogens: organotins and endocrine disruption via nuclear receptor signaling. Endocrinology. 2006, 147 (6 Suppl): S50–5.PubMedCrossRefGoogle Scholar
  24. 24.
    Hatch EE, Nelson JW, Stahlhut RW, Webster TF. Association of endocrine disruptors and obesity: perspectives from epidemiological studies. Int J Androl 2010, 33: 324–32.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Grün F, Watanabe H, Zamanian Z, et al. Endocrine-disrupting organotin compounds are potent inducers of adipogenesis in vertebrates. Mol Endocrinol 2006, 20: 2141–55.PubMedCrossRefGoogle Scholar
  26. 26.
    Lang IA, Galloway TS, Scarlett A, et al. Association of urinary bisphenol A concentration with medical disorders and laboratory abnormalities in adults. JAMA 2008, 300: 1303–10.PubMedCrossRefGoogle Scholar
  27. 27.
    Melzer D, Rice NE, Lewis C, Henley WE, Galloway TS. Association of urinary bisphenol a concentration with heart disease: evidence from NHANES 2003/06. PLoS One 2010, 5: e8673.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Somm E, Schwitzgebel VM, Toulotte A, et al. Perinatal exposure to bisphenol a alters early adipogenesis in the rat. Environ Health Perspect 2009, 117: 1549–55.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Ben-Jonathan N, Hugo ER, Brandebourg TD. Effects of bisphenol A on adipokine release from human adipose tissue: Implications for the metabolic syndrome. Mol Cell Endocrinol 2009, 304: 49–54.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Huc L, Lemarié A, Guéraud F, Héliès-Toussaint C. Low concentrations of bisphenol A induce lipid accumulation mediated by the production of reactive oxygen species in the mitochondria of HepG2 cells. Toxicol In Vitro 2012, 26: 709–17.PubMedCrossRefGoogle Scholar
  31. 31.
    Economou F, Xyrafis X, Livadas S, et al. In overweight/obese but not in normal-weight women, polycystic ovary syndrome is associated with elevated liver enzymes compared to controls. Hormones (Athens) 2009, 8: 199–206.CrossRefGoogle Scholar
  32. 32.
    Hoppe AA, Carey GB. Polybrominated diphenyl ethers as endocrine disruptors of adipocyte metabolism. Obesity (Silver Spring) 2007, 15: 2942–50.CrossRefGoogle Scholar
  33. 33.
    Boberg J, Metzdorff S, Wortzigera R, et al. Impact of diisobutyl phthalate and other PPAR agonists on steroidogenesis and plasma insulin and leptin levels in fetal rats. Toxicology 2008, 250: 75–81.PubMedCrossRefGoogle Scholar
  34. 34.
    Hatch EE, Nelson JW, Qureshi MM, et al. Association of urinary phthalate metabolite concentrations with body mass index and waist circumference: a cross-sectional study of NHANES data, 1999–2002. Environmental Health 2008, 7: 27.PubMedCentralPubMedCrossRefGoogle Scholar
  35. 35.
    Elobeid MA, Padilla MA, Brock DW, Ruden DM, Allison DB. Endocrine disruptors and obesity: an examination of selected persistent organic pollutants in the NHANES 1999–2002 data. Int J Environ Res Public Health 2010, 7: 2988–3005.PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    Alonso-Magdalena P, Morimoto S, Ripoll C, Fuentes E, Nadal A. The estrogenic effect of bisphenol A disrupts pancreatic β-cell function in vivo and induces insulin resistance. Environ Health Perspect 2006, 114: 106–12.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Alonso-Magdalena P, Laribi O, Ropero AB, et al. Low doses of bisphenol A and diethylstilbestrol impair Ca2+ signals in pancreatic α-cells through a nonclassical membrane estrogen receptor within intact islets of Langerhans. Environ Health Perspect 2005, 113: 969–77.PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Fowler PA, Bellingham M, Sinclair KD, et al. Impact of endocrine-disrupting compounds (EDCs) on female reproductive health. Mol Cell Endocrinol 2012, 355: 231–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Fernández M, Bianchi M, Lux-Lantos V, Libertun C. Neonatal exposure to bisphenol a alters reproductive parameters and gonadotropin releasing hormone signaling in female rats. Environ Health Perspect 2009, 117: 757–62.PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Fernandez MO, Bourguignon N, Lux-Lantos V, Libertun C. Neonatal exposure to bisphenol a and reproductive and endocrine alterations resembling the polycystic ovarian syndrome in adult rats. Environ Health Perspect 2010, 118: 1217–22.PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Abbott DH, Barnett DK, Bruns CM, Dumesic DA. Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome? Hum Reprod Update 2005, 11: 357–74.PubMedCrossRefGoogle Scholar
  42. 42.
    West C, Foster DL, Evans NP, Robinson J, Padmanabhan V. Intrafollicular activin availability is altered in prenatally-androgenized lambs. Mol Cell Endocrinol 2001, 185: 51–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Takeuchi T, Tsutsumi O, Ikezuki Y, Takai Y, Taketani Y. Positive relationship between androgen and the endocrine disruptor, bisphenol A, in normal women and women with ovarian dysfunction. Endocr J 2004, 51: 165–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Takeuchi T, Tsutsumi O. Serum bisphenol a concentrations showed gender differences, possibly linked to androgen levels. Bioch Bioph Res Com 2002, 291: 76–8.CrossRefGoogle Scholar
  45. 45.
    Takeuchi T, Tsutsumi O, Ikezuki Y, et al. Elevated serum bisphenol A levels under hyperandrogenic conditions may be caused by decreased UDP-glucuronosyltransferase activity. Endocr J 2006, 53: 485–91.PubMedCrossRefGoogle Scholar
  46. 46.
    Hanioka N, Jinno H, Nishimura T, Ando M. Suppression of male-specific cytochrome P450 isoforms by bisphenol A in rat liver. Arch Toxicol 1998, 72: 387–94.PubMedCrossRefGoogle Scholar
  47. 47.
    Dechaud H, Ravard C, Claustrat F, de la Perriere AB, Pugeat M. Xenoestrogen interaction with human sex hormone-binding globulin (hSHBG). Steroids 1999, 64: 328–34.PubMedCrossRefGoogle Scholar
  48. 48.
    Kandaraki E, Chatzigeorgiou A, Livadas S, et al. Endocrine disruptors and polycystic ovary syndrome (PCOS): elevated serum levels of bisphenol A in women with PCOS. J Clin Endocrinol Metab 2011, 96: E480–4.PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2013

Authors and Affiliations

  1. 1.Endocrine Unit, Third Department of Internal MedicineMedical School University of Athens, Sotiria HospitalAthensGreece
  2. 2.Endocrinology and Metabolism, Head of the Third Department of Medicine, Endocrine UnitMedical School University of AthensAthensGreece

Personalised recommendations